ATE454124T1 - Rekombinante anti-cd30-antikörper und deren verwendungen - Google Patents

Rekombinante anti-cd30-antikörper und deren verwendungen

Info

Publication number
ATE454124T1
ATE454124T1 AT01986050T AT01986050T ATE454124T1 AT E454124 T1 ATE454124 T1 AT E454124T1 AT 01986050 T AT01986050 T AT 01986050T AT 01986050 T AT01986050 T AT 01986050T AT E454124 T1 ATE454124 T1 AT E454124T1
Authority
AT
Austria
Prior art keywords
proteins
hodgkin
disease
antibodies
hefi
Prior art date
Application number
AT01986050T
Other languages
English (en)
Inventor
Joseph Francisco
Grant Risdon
Alan Wahl
Clay Siegall
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24910311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE454124(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of ATE454124T1 publication Critical patent/ATE454124T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01986050T 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen ATE454124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE454124T1 true ATE454124T1 (de) 2010-01-15

Family

ID=24910311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01986050T ATE454124T1 (de) 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen

Country Status (12)

Country Link
US (1) US7090843B1 (de)
EP (1) EP1347730B2 (de)
JP (1) JP4303964B2 (de)
AT (1) ATE454124T1 (de)
AU (2) AU3651802A (de)
CA (1) CA2430135C (de)
CY (1) CY1110700T1 (de)
DE (1) DE60141043D1 (de)
DK (1) DK1347730T4 (de)
ES (1) ES2339333T5 (de)
PT (1) PT1347730E (de)
WO (1) WO2002043661A2 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090843B1 (en) † 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
AU2002363939A1 (en) * 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CA2471645A1 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
JP4562395B2 (ja) 2002-01-09 2010-10-13 メダレックス， インク． Ｃｄ３０に対するヒトモノクローナル抗体
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7659241B2 (en) * 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
AU2005292227A1 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating CD30 positive lymphomas
BRPI0607203A2 (pt) 2005-02-18 2009-08-25 Medarex Inc anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
EP1951757B1 (de) 2005-10-06 2014-05-14 Xencor, Inc. Optimierte anti-cd30-antikörper
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
CR20190516A (es) 2007-07-16 2020-02-18 Genentech Inc ANTICUERPOS ANTI-CD79B E INMUNOCONJUGADOS (Divisional 2015-0040)
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CN101969970B (zh) * 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
CN101981055B (zh) 2008-01-31 2016-03-09 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
CA3051090C (en) 2009-01-09 2022-04-12 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP2793949B1 (de) 2011-12-23 2018-08-22 Innate Pharma Enzymatische konjugation von antikörpern
JP6370774B2 (ja) * 2012-04-27 2018-08-08 ノヴォ ノルディスク アー／エス ヒトｃｄ３０リガンド抗原結合性タンパク質
EP2872894B1 (de) 2012-07-13 2019-04-17 Innate Pharma Screening von konjugierten antikörpern
NZ740948A (en) 2012-10-11 2019-11-29 Daiichi Sankyo Co Ltd Glycinamide derivatives and production methods thereof
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
EP2916872B1 (de) 2012-11-09 2019-02-27 Innate Pharma Kennungen für tgase-vermittelte konjugation
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MY169117A (en) 2012-12-21 2019-02-18 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
BR112015023520A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc purificação do conjugado de anticorpo-fármaco (adc)
TWI689313B (zh) 2013-03-15 2020-04-01 德商艾伯維德國有限及兩合公司 抗-ｅｇｆｒ抗體藥物結合物調配物
EP2968582B1 (de) 2013-03-15 2020-07-01 Innate Pharma Festphasen-tgase-vermittelte konjugation von antikörpern
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
EP3010547B1 (de) 2013-06-20 2021-04-21 Innate Pharma Enzymatische konjugation von polypeptiden
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
CN105764503A (zh) 2013-10-15 2016-07-13 西雅图基因公司 用于改善配体-药物偶联物药代动力学的peg化的药物-接头
AU2015210578B2 (en) 2014-01-29 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
WO2015196167A1 (en) 2014-06-20 2015-12-23 Bioalliance C.V. Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
EP3193915A1 (de) 2014-07-21 2017-07-26 Novartis AG Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
CA2988126A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
LT3380620T (lt) 2015-11-23 2024-09-10 Novartis Ag Optimizuoti lentivirusiniai pernešimo vektoriai ir jų panaudojimas
EP4219689A3 (de) 2015-12-30 2023-12-20 Novartis AG Immuneffektorzelltherapien mit verbesserter wirksamkeit
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
JP7523907B2 (ja) 2016-11-14 2024-07-29 武田薬品工業株式会社 非成人のヒトに対する抗ｃｄ３０抗体－薬物コンジュゲートの投与
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MA50767A (fr) 2017-10-11 2020-08-19 Seattle Genetics Inc Procédés de réduction des effets secondaires d'une thérapie par conjugués de médicament anticorps anti-cd30
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
MX2020004563A (es) 2017-11-01 2020-08-13 Seattle Genetics Inc Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
MA52135A (fr) 2018-03-23 2021-01-27 Seagen Inc Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (de) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Zusammensetzungen und verfahren zur immunonkologie
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11584799B2 (en) 2018-09-24 2023-02-21 Medical College Of Wisconsin, Inc. Anti-CD30 antibodies and methods for treating CD30+ cancer
CA3114137A1 (en) 2018-09-26 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
CA3114922A1 (en) 2018-10-01 2020-04-09 Seagen Inc. Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
EP4032892A4 (de) 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin-derivat und konjugat davon
MX2022003357A (es) 2019-09-25 2022-05-03 Seagen Inc Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
EP4037717A1 (de) 2019-10-04 2022-08-10 Seagen Inc. Camptothecin-peptidkonjugate
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
MX2022005240A (es) 2019-11-04 2022-08-19 Seagen Inc Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
KR20220130160A (ko) 2020-01-22 2022-09-26 상하이 센후이 메디슨 컴퍼니 리미티드 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
WO2021155129A1 (en) 2020-01-31 2021-08-05 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
US20230165969A1 (en) 2020-03-25 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
AU2021243080A1 (en) 2020-03-25 2022-09-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
EP4149559A1 (de) 2020-05-13 2023-03-22 Seagen Inc. Verfahren zur behandlung von krebs mit einer kombination aus anti-cd30-antikörper-wirkstoff-konjugaten
EP4165169A1 (de) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitoren und deren verwendungen
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
AU2022208054A1 (en) 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024514673A (ja) 2021-04-20 2024-04-02 シージェン インコーポレイテッド 抗体依存性細胞傷害の調節
EP4330381A1 (de) 2021-04-27 2024-03-06 Novartis AG System zur herstellung von viralen vektoren
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
KR20240099363A (ko) 2021-10-29 2024-06-28 씨젠 인크. 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024197151A2 (en) 2023-03-22 2024-09-26 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
WO1994015969A1 (en) 1993-01-14 1994-07-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
JP3066983B2 (ja) 1995-01-18 2000-07-17 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
US20030186384A1 (en) 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) † 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Also Published As

Publication number Publication date
AU3651802A (en) 2002-06-11
US7090843B1 (en) 2006-08-15
JP2005506035A (ja) 2005-03-03
CY1110700T1 (el) 2015-06-10
ES2339333T3 (es) 2010-05-19
AU2002236518B2 (en) 2006-10-26
PT1347730E (pt) 2010-03-03
DK1347730T4 (da) 2020-04-27
WO2002043661B1 (en) 2003-03-06
WO2002043661A2 (en) 2002-06-06
CA2430135A1 (en) 2002-06-06
DE60141043D1 (de) 2010-02-25
EP1347730A2 (de) 2003-10-01
JP4303964B2 (ja) 2009-07-29
EP1347730A4 (de) 2005-08-17
ES2339333T5 (es) 2013-09-26
DK1347730T3 (da) 2010-02-01
WO2002043661A3 (en) 2003-01-16
CA2430135C (en) 2012-10-02
EP1347730B2 (de) 2013-05-29
EP1347730B1 (de) 2010-01-06

Similar Documents

Publication Publication Date Title
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
KR102486090B1 (ko) 생체 내 내성이 높은 항체 약물 결합체
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
US20220226441A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
WO2002061090A3 (en) Prokaryotically produced antibodies and uses thereof
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
DE69520739T2 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
FI3773738T3 (fi) Vasta-aine-lääkekonjugaatteja ja niiden käyttöjä syövän hoitamiseksi
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1347730

Country of ref document: EP